Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leukemia (CLL) cells to specific microenvironments. Here we have investigated whether the CX 3 CR1/CX 3 CL1 axis is involved in the interaction of CLL with their microenvironment. CLL cells from 52 patients expressed surface CX 3 CR1 and CX 3 CL1 and released constitutively soluble CX 3 CL1. One third of these were attracted in vitro by soluble CX 3 CL1. CX 3 CL1-induced phosphorylation of PI3K, Erk1/2, p38, Akt and Src was involved in induction of CLL chemotaxis. Leukemic B cells upregulated CXCR4 upon incubation with CX 3 CL1 and this was paralleled by increased chemotaxis to CXCL12. Akt phosphorylation was involved in CX 3 CL1-induced upregulation of CXCR4 on CLL. In proliferation centers from CLL lymph node and bone marrow, CX 3 CL1 was expressed by CLL cells whereas CX 3 CR1 was detected in CLL and stromal cells. Nurselike cells (NLCs) generated from CLL patient blood co-expressed surface CX 3 CR1 and CX 3 CL1, but did not secrete soluble CX 3 CL1. Only half of NLC cell fractions were attracted in vitro by CX 3 CL1. In conclusion, the CX 3 CR1/CX 3 CL1 system may contribute to interactions between CLL cells and tumor microenvironment by increasing CXCL12-mediated attraction of leukemic cells to NLC and promoting directly adhesion of CLL cells to NLC.
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of long-lived CD5 þ B lymphocytes in the peripheral blood, bone marrow and secondary lymphoid organs. 1 The presence or absence of somatic mutations of immunoglobulin variable heavy chain (IGHV) genes in malignant cells is the best predictor of clinical outcome of CLL patients. In particular, unmutated IGVH genes are associated with more aggressive course and shorter survival as compared with mutated cases. 2, 3 Additional prognostic markers are surface CD38 and intracellular ZAP-70 whose expression in leukemic cells correlates with unfavorable clinical outcome. 2, 4, 5 Finally, different chromosomal abnormalities detected in CLL such as 13q deletion, 17deletion, 11q deletion and 12q trisomy are prognostically relevant. 6 Chemokines are low molecular weight cytokines specialized in leukocyte recruitment to inflammatory sites and in the correct positioning of lymphocytes in secondary lymphoid organs. 7 Chemokines are also involved in different pathological processes including growth and dissemination of solid tumors and hematological malignancies. 8, 9 Several chemokines/chemokine receptors control the migration of CLL cells to lymph nodes, secondary lymphoid organs and bone marrow. Extravasation and migration across endothelium are mediated by CCR7, expressed on CLL cells, and its ligands CCL21 and CCL19 expressed on high endothelial venules of secondary lymphoid organs. 10 CLL cells overexpress CXCR5 that interacts with its ligand CXCL13 produced by CD68 þ macrophages in lymphoid tissues, thus contributing to leukemic cell migration to the latter sites. 11 Finally, migration of CLL cells to bone marrow is mediated by CXCR4, highly expressed in leukemic cells, and its ligand CXCL12, produced by stromal cells. 12 CX 3 CL1/fractalkine, a chemokine constitutively expressed by many hematopoietic and non-hematopoietic tissues, 13, 14 is synthesized as membrane-bound protein but can also be released by proteolytic cleavage. Membrane-bound CX 3 CL1 functions as an adhesion molecule whereas the secreted form triggers chemotaxis of lymphocytes and monocytes to inflammatory sites. 13, 15 CX 3 C chemokine receptor 1 (CX 3 CR1), the receptor for CX 3 CL1, is expressed on human NK cells, monocytes, T lymphocytes, mast cells 13, 16 as well as on B cells. 17 Previous studies have shown that CX 3 CR1 is upregulated in different types of B cell lymphoma and in CLL. However, the functional role of CX 3 CR1 in these malignancies has not been addressed. 18, 19 Other studies performed in breast, prostate, 20, 21 pancreatic adenocarcinoma 22 and glioma 23 models have shown that CX 3 CR1 is involved in metastatic spreading of tumor cells to specific tissues expressing CX 3 CL1.
Here we have investigated the functional role of the CX 3 CR1/ CX 3 CL1 axis in CLL and found that these molecules are involved in the cross-talk between tumor cells and their microenvironment.
Patients and methods

Patients
Blood samples were obtained from 52 CLL patients after informed consent in accordance with Helsinki Declaration and study approval by the Institutional Review Boards of the University of Eastern Piedmont, Novara and the National Cancer Research Institute, Genova. CLL diagnosis rested upon, blood count of at least 5 Â 10 9 B lymphocytes per litre, immunoglobulin (Ig) light chain restriction, co-expression of CD19, CD5 and CD23, low expression of surface Ig and absent or low expression of CD79b on CLL. 6 Clinical and laboratory features of CLL patients were as follows: (i) patient age: median 65, range 43-85 years; (ii) sex: 30/52 males and 22/52 females; (iii) no treatment at study entry for at least 2 months; (iv) median B lymphocyte count 13.5 Â 10 9 /l with at least 85% CD19 
Cell isolation and cultures
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradients and cryopreserved in freezing solution containing 50% RPMI 1640 (Sigma Chemical Company, St Louis, MO, USA), 40% fetal bovine serum (Sigma), and 10% DMSO (Sigma). After thawing, PBMNCs were depleted of CD3 þ , CD56 þ and CD14 þ cells by immunomagnetic bead manipulation (Milteny Biotec Inc., Auburn, CA, USA). 24 Negatively selected cells contained at least 95% leukemic cells, as assessed by double staining for CD19 and CD5. In some experiments, CLL cells were positively selected by CD19-conjugated immunomagnetic beads. These cells were cultured for 24-48 h with medium or 100 ng/ml CD40 ligand (Immunotools, Friesoythe, Germany) and 2 mg/ml anti-Ig (Jackson Immunoresearch, Baltimore, MD, USA). Soluble CX 3 CL1 was measured by enzyme-linked immunosorbent assay (R&D System Inc., Minneapolis, MN, USA).
Antibodies and reagents
The following mAbs were used: CD19-PE/cyanin (Cy)5, CD38-PE/Cy5, CD5-PE, 45-PE/Cy5 from Caltag Laboratories (Burlingame, CA, USA); CD38-PE/-FITC and goat anti-rabbit Ig-PE/FITC from Serotec Inc. (Raleigh, NC, USA); goat anti-rabbit IgG Alexafluor 488 from Invitrogen (Carlsbad, CA USA); CD19-allophycocyanin (APC), anti-CXCR5-PE, anti-CCR7-PE and anti-CXCR4-PE mAbs from BD Pharmingen (San Diego, CA, USA); CD68-FITC/PE, CD14-FITC, CD83-FITC, CD3-PE, and HLA-DR-FITC/PE from BD Biosciences (San Josè, CA, USA). Unconjugated rabbit anti-human CX 3 CR1 and rabbit anti-human CX 3 CL1 were from Serotec and Peprotech (Rocky Hill, NY, USA), respectively, unconjugated CD3, CD56, CD14, and vimentin (V9) mAbs from DAKO (Glostrup, Denmark) and unconjugated anti-VEGF-A mAb from R&D System Inc.
Cells were stained with fluorochrome-conjugated or unconjugated antibodies followed by secondary reagents. Isotype and fluorochrome-matched antibodies were tested as controls. For intracellular staining, cells were fixed, permeabilized, incubated with unconjugated mAb, followed by secondary reagent and analyzed. Cells were run on a FACSCalibur instrument (BectonDickinson, BD, Franklin Lakes, NJ, USA). For each analysis 10 000 events were acquired and analyzed using CellQuest software (BD). Results were expressed as either percentage of positive cells or mean fluorescence intensity ratio (MFIR), calculated by dividing the MFI of cells stained with specific mAb by the MFI of cells stained with isotype-control mAb. In some experiments, cells were analyzed using a FACSort (BD Biosciences), acquiring a minimum of 1500 events. Data were analyzed using the WindMDI software (freely downloadable at http://facs.scripps.edu/software.html)
Chemotaxis assay
PBMCs (5 Â 10 5 ) were dispensed in the upper chamber of 24-transwell plates of polycarbonate membrane with 5 mm poresize (Costar, Cambridge, MA, USA), and increasing concentrations (10, 100, 300, 600, 1000 ng/ml) of rCX 3 CL1 (R&D System) or medium alone (nil) were added to the lower chamber. 17 The rCXCL12 (R&D System) was tested at 300 ng/ml. Plates were incubated for 2 h at 37 1C. Transmigrated cells were harvested, counted and identified by staining with CD19/CD5 mAbs. Each experiment was performed in triplicate and results were expressed as percentage of input calculated as ratio between rCX 3 CL1-induced migration and spontaneous migration. In some experiments, CLL cells were pretreated 1 h at 37 1C with 100 ng/ml pertussis toxin (PTX) (Sigma) and subjected to chemotaxis to rCX 3 CL1 (ref. 17) . In other experiments, CLL cells were preincubated for 1 h at 37 1C with the following: PI3K inhibitor LY294002 (20 mM; Sigma), Akt inhibitor (1 mM; Calbiochem, Gibbstown, NJ, USA), MEK inhibitor PD98059 (1 mM; Biomol, Plymouth, Meeting, PA, USA), p38 inhibitor SB203580 (1 mM; Biomol), Src family inhibitor PP1 (10 mM; Calbiochem) or medium alone before being tested for CX 3 CL1-driven chemotaxis. CLL migration to CXCL12 (300 ng/ml) was tested following overnight culture with 300 ng/ml CX 3 CL1 or medium alone. Nurselike cells (NLCs) were plated at 5 Â 10 4 per well in the upper chamber of 24-transwell plates of polycarbonate membrane with 8 mm pore-size (Costar). The rCX 3 CL1 was added to the lower chamber at 300 ng/ml. Plates were incubated for 20 h at 37 1C. Three aliquots of 100 ml were then recovered from each lower chamber and counted for 1 minute under a defined flow rate using a FACSort (BD) to obtain the median relative number of total transmigrated cells. Adherent cells were distinguished from lymphocytes by flow cytometry using physical parameters.
Western blot
Western blot analysis of MAPK phosphorylation was performed as reported 25 following cell incubation with or without 300 ng/ml rCX 3 CL1 for 2, 10, 20, 30, 60 min. Antibodies to phoshorylated (p) or unphosphorylated Src, p38, Akt, and Erk1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used. Images of immunoblots were scanned and quantified by Scion Image Analysis program (release beta 2) from Scion (Frederick, MD, USA). Ratios between values of the most intense band following rCX 3 CL1 treatment and those at time 0 are expressed as mean fold increase ± s.e. from five independent experiments.
RNA extraction and quantitative real-time PCR
RNA was extracted using RNeasy Plus Mini kit (Qiagen, Hilden, Germany) and converted to cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Monza, Italy). Quantitative real-time PCR was performed using the 7900 HT Fast Real Time PCR System (SDS2.3 software, Applied Biosystems). Specific primers for CX 3 CL1, CX 3 CR1 and housekeeping genes b-actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were commercially available (TaqMan Gene Expression Assays, all from Applied Biosystems). Reactions were performed in triplicate from the same cDNA reaction (technical replicates). The comparative CT method was used to calculate the relative expression of the gene under analysis. For each sample, the CT value of the gene under analysis was normalized with the formula DCT ¼ CT of the gene under analysis-CT endogenous control gene. For relative expression, the mean DCT was determined and the relative expression of the gene under analysis was calculated with the expression 2 ÀDCT .
Generation of NLCs
NLCs were generated from PBMCs of CLL patients. 26, 27 . Briefly, PBMCs (3x10 6 /ml) were dispensed in 24-well plates and incubated for 2 weeks in RMPI 1640 with 10% fetal bovine serum, changing medium every 5 days. Morphological differentiation of cultures (that is, presence of large multinucleated polygonal cells surrounded by small live lymphocytes) was checked after 2 weeks by Giemsa staining. A variable number of adherent cells (4 Â 10 3 -10 Â 10 3 ) was obtained from each well. Loosely adherent lymphocytes were removed from cultures by robust washing and collected for quantitative real-time studies. Adherent cells were detached manually using a Trypsin-EDTA solution (Sigma) and viability checked by the Trypan blue exclusion test. Cells were subsequently analyzed by flow cytometry, keeping forward and side scatter parameters constant for each acquisition. Irrelevant isotype-matched antibodies were used to set the basal level of fluorescence. At least 50 000 events within the morphological gate were acquired for each sample. Data were processed using the WindMDI software. In some experiments, NLCs were cultured in medium alone for 7, 14, and 21 days. Supernatants were collected and tested for CX 3 CL1 by enzyme-linked immunosorbent assay.
Confocal microscopy experiments
PBMCs from CLL patients were plated at 2.5 Â 10 6 /ml and incubated on glass coverslips for 2 weeks in RPMI 1640 with 10% fetal bovine serum to generate NLCs. Coverslips were then removed from culture, washed to eliminate floating cells and incubated with rabbit anti-CX 3 CR1 or -CX 3 CL1 followed by Texas-red conjugated goat anti-rabbit IgG (Invitrogen). Irrelevant isotype-matched antibodies were used as controls. Cells were fixed, mounted on slides and analyzed using an Olympus 1 Â 70 FV10 confocal microscope at Â 60 magnification (Olympus, Milan, Italy), equipped with the FluoView software (Olympus). Images were processed using Adobe Photoshop CS3 software (Adobe, San Jose, CA, USA).
Immunohistochemical studies
Formalin-fixed and paraffin-embedded sections of either lymph nodes infiltrated by CLL cells, or lymph nodes with reactive follicular hyperplasia were collected from the archives of the Department of Human Pathology of the University of Palermo, Italy. The 4 mm thick sections of tissue were cut from paraffin blocks and put on slides. Sections were deparaffinized and rehydrated and subsequently microwave-oven treated in citrate buffer Tris-HCl/ EDTA pH 9.0 (DakoCytomation, Glostrup, Denmark) for antigen retrieval. Following neutralization of endogenous peroxidases with H 2 O 2 for 10 min, the sections were incubated with protein block Novocastra (Newcastle, UK) for 10 min. Sections were then incubated overnight at 4 1C with the primary polyclonal rabbit anti-human CX 3 CR1 (dilution 1:100, Novus Biologicals, Littleton, CO, USA) and rabbit antihuman CX 3 CL1 antibodies (dilution 1:100, Peprotech). Normal mouse serum was used instead of primary antibodies as negative control. Staining was revealed by a polymer detection system based on the streptavidin-biotin peroxidase complex (Strept-ABC) method (Novolink max polymer detection system, Novocastra) using DAB (3,3 0 -diaminobenzidine, Novocastra) substrate-chromogen. After counterstaining with hematoxylin (Novocastra), the sections were evaluated under a Leica DM2000 optical microscope (Leica, Wetzlar, Germany) and captions were collected using a Leica DFC320 digital camera. For double immunohistochemical analysis, tissue sections were processed as above and, after Fc blocking, incubated with mouse anti-human Ki67 (DakoCytomation), whose binding was revealed by LSAB þ System-HRP (DakoCytomation) and DAB substratechromogen (Novocastra). Slides were then incubated with either rabbit anti-human CX 3 CR1 (Novus Biologicals) or rabbit antihuman CX 3 CL1 (Peprotech, USA). Stainings were revealed by the LSAB þ System-AP (DakoCytomation) and permanent red substrate-chromogen (DakoCytomation). Stained slides were counterstained with hematoxylin. For immunofluorescence analysis on confocal microscopy, tissue sections were processed as above and, after Fc blocking, incubated with primary antibody antihuman CD68 (Novocastra, diluition 1:200) whose binding was revealed by Alexa 568-conjugated goat anti-mouse (Invitrogen, Molecular Probes, Carlsbad, CA, USA) secondary antibody. Subsequently the slides were incubated with primary antibodies rabbit anti-human CX 3 CR1 (Novus Biologicals, diluition 1:100) and CX 3 CL1 (Peprotech, diluition 1:100), which were revealed by Alexa 488-conjugated goat anti-rabbit secondary antibody (Invitrogen Molecular Probes). Slides were evaluated by using a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems, Milan, Italy).
Statistical analysis
Data were reported in box plot in terms of medians, first and third quartiles, minimun and maximum values. For some experiments data were represented in histograms as mean ± s.e. The Mann-Whitney U-test was used to compare quantitative variables between two groups of observation. A P-value of o0.05 was considered statistically significant. Statistical analyses were performed using Graph Pad Prism 3 software (GraphPad Software, La Jolla, CA, USA) and the statistical package 'Statistica 6'.
Results
The CX 3 CR1/CX 3 CL1 axis in CLL þ CLL cells from 20 patients showed that all samples expressed CX 3 CR1 mRNA at highly variable levels ( Figure 1a, right panel) .
Chemotaxis of 52 CLL cell fractions to CX 3 CL1 was next investigated in a transwell assay. Seventeen/52 samples migrated whereas the remaining 35 did not. The 100, 300 and 600 ng/ml CX 3 CL1 increased significantly (P ¼ 0.020 for 100, P ¼ 0.0040 for 300, P ¼ 0.026 for 600 ng/ml) spontaneous migration of CLL cell suspensions (Figure 1b) . Five/17 of these (Figure 1b, medium panel) , as well as to CXCL12 tested as control (Figure 1b, right panel) .
PBMCs from the same CLL samples were next stained with CD19, CD5 and anti-CX 3 CL1 mAbs and tested for CX 3 CL1 expression after gating on CD19 þ CD5 þ cells. CX 3 CL1 was detected on the surface of all leukemic cell samples (median PBMCs were tested in a transwell assay and migrated cells were identified by flow cytometry using CD19 and CD5 mAbs. The figure shows a dosedependent curve with different rCX 3 CL1 concentrations. CXCL12 was tested at 300 ng/ml as positive control. Results are expressed as median percentage of input between CX 3 CL1-induced migration and spontaneous migration from 17 different CLL samples (right panel). *P ¼ 0.020 and P ¼ 0.026 for 100 and 600 ng/ml, respectively. **P ¼ 0.0040 for 300 ng/ml. Five CLL suspensions were pretreated with 100 ng of PTX and subsequently subjected to chemotaxis to 300 ng/ml rCX 3 CL1 (medium panel) and 300 ng/ml rCXCL12 (right panel), tested as control. Purified CLL cells incubated in the absence of stimuli for 24 h released soluble CX 3 CL1 (mean pg/ml: 807, range 190-3850) (Figure 1d ). The rCD40 L stimulation of leukemic cells did not increase CX 3 CL1 production (not shown). Addition of exogenous CX 3 CL1 to 4-day cultures of CLL cells had no influence on cell survival or proliferation (not shown).
No correlation was found between CX 3 CR1 or CX 3 CL1 MFIR and IGVH mutational status, or ZAP70 or CD38 positivity or negativity. Chemotaxis of malignant cells to CX 3 CL1 was detected more frequently in IGVH-mutated (12/17 CLL cases) than IGVH-unmutated cases (5/17), but was equally distributed in ZAP70 þ and ZAP70 À or CD38 þ and CD38 À cases.
CX 3 CL1-driven signal transduction in CLL cells
To investigate the mechanisms underlying the differences in CX 3 CL1-induced chemotaxis of CLL, signal transduction experiments were next performed. Five purified leukemic cell suspensions that migrated to CX 3 CL1 were incubated for different times with or without CX 3 CL1 and subjected to western blot or immunoprecipitation analyses using antibodies against unphoshorylated and phosphorylated (p)-p38, Akt, Erk1 and Erk2 and Src. 29 Quantitative analysis of the bands was performed by densitometry. Akt, Erk1, Erk2, and Src, but not p38 were constitutively phosphorylated in all CLL suspensions (Figure 2a) . Following incubation of all CLL suspensions with CX 3 CL1, p-p38 expression was induced after 2 min and peaked after 10 min (mean fold increase ¼ 4.4), p-Akt peaked after 2 min (mean fold increase ¼ 2.7), p-ERK1 after 2 min (mean fold increase ¼ 3.5), p-ERK2 after 10 min (mean fold increase ¼ 11.0) and p-Src after 2 min (mean fold increase ¼ 1.9). Unphosphorylated p38, Akt, Erk1, Erk2 and Src bands did not change in intensity following treatment with CX 3 CL1 at any time tested (Figure 2a) .
Next, five purified leukemic B cell suspensions that did not migrate to CX 3 CL1 were incubated for different times with or without CX 3 CL1 and processed as above. No p-p38, p-ERK1, p-ERK2 or p-Src bands were detected in any leukemic cell fraction incubated with or without CX 3 CL1 (Figure 2b) . In contrast, p-Akt was constitutively expressed in all CLL cell suspensions and increased following incubation with CX 3 CL1 peaking after 10 min (mean fold increase ¼ 2.8).
Finally, eight CLL suspensions that migrated to CX 3 CL1 were subjected to chemotaxis following pre-incubation with PI3K inhibitor LY294002 (20 mM), Akt inhibitor (1 mM), the MEK inhibitor PD98059 that targets ERK1/2 (1 mM), the p38 inhibitor SB203580 (1 mM), the Src family inhibitor PP1 (10 mM) or medium alone. Chemotaxis to CX 3 CL1 was significantly decreased by pretreatment with MEK/Erk1-2 (P ¼ 0.015), p38 (P ¼ 0.008), Akt (P ¼ 0.020), PI3K (P ¼ 0.029) and Src (P ¼ 0.014) inhibitors (Figure 2c ).
CX 3 CL1 upregulates CXCR4 and CXCL-12-driven chemotaxis through Akt phosphorylation
We next asked whether treatment of CLL cells with CX 3 CL1 affected the expression and/or function of CXCR4. Following preliminary time course and dose response experiments, PBMCs from 52 CLL patients were pre-incubated overnight with 300 ng/ml CX 3 CL1 or medium, and tested for CXCR4 expression and chemotaxis to CXCL12. A significant increase in CXCR4 MFIR (Po0.0001) was found in all CLL samples following incubation with CX 3 CL1 vs medium alone (Figure 3a, left panel) . Under the same conditions, CX 3 CL1 significantly increased (Po0.0001) CXCL12-induced leukemic cell chemotaxis over background levels (Figure 3a, right panel) . CX 3 CL1 induced upregulation of CXCR4 was unaffected by pretreatment of CLL cells with PTX (data not shown).
No correlation was found between CXCR4 MFIR on CLL cells following incubation with CX 3 CL1 vs medium and IGVH mutational status, or ZAP70 or CD38 positivity or negativity.
In contrast to that observed with CXCR4, no difference in CXCR5 and CCR7 MFIR was observed in CLL from 10 patients incubated as above with CX 3 CL1 or medium (median CXCR5 MFIR in control: 168.1, range 72. 8 To investigate the signaling pathway involved in CX 3 CL1-mediated upregulation of CXCR4 and CXCL12-induced chemotaxis, eight CLL cell suspensions (four that migrated to CX 3 CL1 and four that did not) were first pre-incubated for 1 h at 37 1C with PI3K inhibitor LY294002, Akt inhibitor, the MEK inhibitor PD98059, the p38 inhibitor SB203580, or the Src family inhibitor PP1 and subsequently cultured overnight with CX 3 CL1. were first pre-incubated overnight with 300 ng/ml CX 3 CL1 or medium alone and subsequently stained with CD19, CD5 and anti-CXCR4 mAbs. Cells were analyzed by flow cytometry after gating on CD19 þ CD5 þ cells. Results are expressed in box plot as median MFIR, first and third quartiles, maximum and minimum. ***Po0.0001. Right panel: leukemic cells were cultured overnight as above and subsequently tested in a transwell assay in response to 300 ng/ml rCXCL12. Transmigrated cells were harvested, counted and identified by double staining with CD19/CD5 mAbs. Results are expressed as median percentage of input between rCXCL12-induced migration and spontaneous migration. ***Po0.0001. (b) Eight CLL suspensions (four that migrated to CX 3 CL1 and four that did not) were pre-incubated for 1 h at 37 1C with PI3K inhibitor LY294002, Akt inhibitor, MEK inhibitor PD98059 that targets ERK1/2, p38 inhibitor SB203580, or Src family inhibitor PP1 and subsequently incubated overnight with medium alone (nil) or 300 ng/ml CX 3 CL1. Thereafter, cells were stained with an anti-CXCR4 mAb and MFIR was determined. Results are expressed in box plot as median MFIR, first and third quartiles, maximum and minimum. **P ¼ 0.002.
Thereafter, cells were stained with an anti-CXCR4 mAb and MFIR determined. CXCR4 MFIR was significantly decreased in CLL cells after exposure to Akt inhibitor (P ¼ 0.002), but not to the other inhibitors (Figure 3b) . Thus, CX 3 CL1-induced Akt phosphorylation was involved in CXCR4 upregulation on CLL cells irrespective of they migrated or not to CX 3 CL1.
CX 3 CR1/CX 3 CL1 expression in lymph nodes from CLL patients CX 3 CR1 and CX 3 CL1 expression in paraffin-embedded, formalin-fixed lymph node tissue sections from CLL patients were investigated by immunohistochemistry. Six lymph node samples showing a complete effacement by CLL cells were selected for these experiments. In CLL samples, CX 3 CR1 was diffusely expressed by leukemic cells and by the meshwork of spindle and stellate 'stromal' cells intermingling with lymphoid elements (Figure 4a) . A similar staining pattern was detected in germinal centers of lymph nodes with reactive follicular hyperplasia (Figure 4c ). CX 3 CL1 expression was mostly confined to the CLL neoplastic clone, marking both small neoplastic lymphocytes and larger cells (Figure 4b ). CX 3 CL1 staining pattern was similar to that observed in B cells populating germinal centers from lymph nodes with reactive follicular hyperplasia (Figure 4c ).
To investigate whether CX 3 CR1/CX 3 CL1 expression was more conspicuous in CLL proliferation centers, we performed double immunohistochemistry experiments using an anti-human Ki-67 in combination with anti-CX 3 CR1 or CX 3 CL1 antibodies ( Supplementary Figure 1 SI, panels a-d) . CX 3 CR1/CX 3 CL1 expression was analyzed in six CLL lymph nodes in areas with the highest and lowest densities of Ki-67 þ proliferating cells. The number of cells co-expressing CX 3 CR1 or CX 3 CL1 and Ki-67 was counted out of five high power microscopic fields (HPF, Â 400) characterized by high Ki-67 expression and five HPF with low Ki-67. The percentage of CX 3 CR1
þ /Ki-67 þ and CX 3 CL1
þ /Ki-67 þ in the highest density areas was 35 ± 5 and 42±4, respectively, whereas in the lowest density areas the percentage was 20 ± 5 for CX 3 CR1
þ /Ki-67 þ and 23 ± 4 for Figure 1SI , panel e). Proliferation centers in BM biopsies showed the same patterns of CX 3 CR1 and CX 3 CL1 expression as those detected in lymph nodes (Supplementary Figure 2SI) . A picture similar to that observed in CLL-involved lymph nodes was detected in bone marrow nodular infiltrates from CLL patients, as far as CX 3 CR1 and CX 3 CL1 immunohistochemical expression is concerned (Supplementary Figure 2SI) .
Expression of CX 3 CR1/CX 3 CL1 on 'NLCs' from CLL patients
We next generated in vitro NLCs from PBMCs of 20 CLL patients. NLCs are large, round, adherent cells that express CD68 as distinctive marker. 26, 27 NLCs yield from cultures of PBMC was highly variable, with the percentage of CD68 Table 1SI ). Expression of CX 3 CR1 was confirmed by real-time PCR analyses, performed on eight NLC cultures by comparing adherent cells to lymphocytes in suspension. Cells were purified manually and purity was checked by evaluating physical parameters using the cytofluorimeter, with the two population clearly distinct. Results showed that the CX 3 CR1 mRNA was expressed at variable levels in the adherent component (bona fide NLC) (Supplementary Figure 3SI) . Cells in suspension, comprised of live CLL cells, also expressed CX 3 CR1 mRNA at Btwo-fold higher levels (Supplementary Figure 3SI) . Confocal microscopy studies confirmed that both CX 3 CR1 and CX 3 CL1 were present on the cell surface, with the highest density observed in NLCs surrounded by live CLL cells (Figure 5a ). Proliferation centers from CLL patients contain CD68 þ myeloid cells that have been proposed to represent the tissue counterparts of NLCs. 30 On this basis, we investigated the expression of CX 3 CR1 and CX 3 CL1 on CD68 þ cells populating CLL infiltrates, by double immunofluorescence and confocal microscopy on tissue sections from CLL-involved lymph node samples and control lymph nodes with reactive follicular hyperplasia. As shown in Figure 5b , in CLL samples the cellular meshwork stained by CX 3 CR1 immunolabeling was in part represented by CD68-expressing cells, whereas in reactive lymph nodes the CX 3 CR1 staining was not shared by CD68 þ cells. In both CLL and reactive lymph node samples CD68 þ cells did not show significant expression of CX 3 CL1.
When chemotaxis of NLCs to CX 3 CL1 was tested, spontaneous migration of 6/12 NLC cell suspensions was significantly increased by the chemokine (P ¼ 0.020) (Figure 5c ). In spite of surface CX 3 CL1 expression, NLCs did not secrete the soluble form as assessed by enzyme-linked immunosorbent assay.
Discussion
We have previously demonstrated that CX 3 CL1 controls the trafficking of human CX 3 CR1
þ centrocytes in the germinal /well in the upper chamber of 24-transwell plates of polycarbonate membrane with 8 mm pore-size. The rCX 3 CL1 was added to the lower chamber at 300 ng/ml concentration. Plates were incubated for 20 h at 37 1C. After incubation, three aliquots of 100 ml were recovered from each lower chamber. These samples were counted for 1 min under a defined flow rate using a FACSort. Results are expressed as mean number of migrated cells ± s.e. *P ¼ 0.020. center light zone and likely influences their in vivo survival and differentiation. 17 Here we have investigated whether the CX 3 CL1/CX 3 CR1 axis is expressed in CLL and has a role in their interaction with tumor microenvironment. CX 3 CR1 was expressed by all CLL suspensions tested but only one third of them were attracted in vitro by CX 3 CL1. We have reported that normal naïve and memory B cells, as opposed to germinal centre B cells, were not attracted by CX 3 CL1 (ref. 17 ). These differences were associated with distinctive patterns of CX 3 CL1-initiated signal transduction.
To gain more insight into the mechanisms underlying the heterogeneous chemotactic responsiveness of CLL suspensions to CX 3 CL1, we performed signal transduction experiments with migrating and non-migrating malignant cell fractions. Upon incubation with CX 3 CL1, the former cells showed increased phosphorylation of PI3K, Erk1/2, Akt and Src and de novo induction of p-p38 (ref. 29) , similar to that reported for normal germinal center B cells. 17 Studies with specific inhibitors demonstrated that all of the above kinases were involved in CX 3 CL1-induced chemotaxis, indicating that the PI3K and Src platforms integrated signals from either scaffold.
31,32 CX 3 CL1-induced Akt phosphorylation only was detected in CLL cell fractions not attracted by the chemokine, as reported for normal non-GC B cells. 17 All leukemic B-cell samples upregulated significantly CXCR4 expression upon incubation with CX 3 CL1 and this was paralleled by increased chemotaxis to CXCL12. CXCR4 upregulation was significantly counteracted by Akt inhibitor, irrespective of CLL cell fractions that were attracted or not by CX 3 CL1. CX 3 CL1-induced chemotaxis was abolished, whereas CXCR4 upregulation was unaffected by PTX pretreatment. 33 Therefore, leukemic cells that migrated to CX 3 CL1 utilized two different signaling pathways for CX 3 CL1-induced chemotaxis and CXCR4 upregulation, respectively, sharing Akt phosphorylation but differing for PTX sensitivity.
A distinctive feature of the CLL microenvironment is the formation of proliferation centers of CLL cells not found in other lymphoproliferative disorders. 34 Proliferation centers contain stromal cells, CD68 þ myeloid cells that may be related to NLCs, 30 activated T-helper cells and even follicular dendritic cells, all of which provide anti-apoptotic and proliferative stimuli to tumor cells. 30 We found that both CX 3 CL1 and CX 3 CR1 were in the lymph node and bone marrow from CLL patients. CX 3 CL1 was expressed predominantly by the neoplastic elements whereas CX 3 CR1 was detected in both the latter cells and stromal cells. In particular, CD68 þ myeloid cells were found to co-express CX 3 CR1 but not CX 3 CL1. Cycling CLL cells co-expressing Ki-67 with either CX 3 CL1 or CX 3 CR1 were enriched in proliferation centers.
NLCs differentiate in vitro into large, adherent cells from blood monocytes co-cultured with CLL. 26, 27 NLCs secrete CXCL12 (ref. 26 ) and CXCL13 (ref. 11) that attract CLL cells via CXCR4 and CXCR5, respectively, and protect them from spontaneous or drug-induced apoptosis. 26, 35 NLCs express additional molecules providing survival signals to CLL via the respective receptors such the TNF family members B-cellactivating factor (BAFF) and a proliferation-inducing ligand (APRIL) (ref. 35 ) and CD31 together with plexin-B1 (ref. 36) . NLCs here generated from CLL PBMCs expressed CX 3 CL1 and CX 3 CR1 on the cell surface. However, no soluble CX 3 CL1 was released in NLC culture supernatants and only a half of the NLC suspensions were attracted by CX 3 CL1. In contrast, CLL expressed CX 3 CL1 on the cell surface and released constitutively the soluble chemokine in culture supernatants. These results suggest that (i) CX 3 CL1 may serve as adhesion molecule in NLCs 13, 15 and (ii) NLCs from a subgroup of CLL patients only may be attracted by CLL cell-derived CX 3 CL1 due to reasons that remain to be established.
The results of this study delineate a previously unrecognized role of the CX 3 CL1/CX 3 CR1 axis in the interaction between CLL cells and their microenvironment. We propose that phenotypic and functional upregulation of CXCR4 on CLL cells induced by binding of soluble CX 3 CL1 to CX 3 CR1 enhances the attraction of leukemic cells towards NLCs-secreting CXCL12, that acts as a pro-survival factor for CLL cells. 26 In subsets of patients, NLCs can in turn be attracted by CLL-derived soluble CX 3 CL1. Once in contact, adhesion of NLCs and CLL cells may be strengthened by homotypic (CLL to CLL or NLC to NLC) or heterotypic (CLL to NLC) interactions driven by surface CX 3 CL1 and CX 3 CR1. All of the above may translate into modulation of CLL survival.
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